Skip to main content
. 2015 Oct 26;6(35):38166–38180. doi: 10.18632/oncotarget.6241

Figure 1. HT-29 and LIM1215 tumour xenograft treatment.

Figure 1

A. HT-29 (2×106 cells/site) and B. LIM1215 (5×106 cells/site) were injected subcutaneously into BALB/c mice inguinal regions. Tumour volumes were measured at indicated times (n = 5; mean tumour volume ± SEM; *P < 0.05). Treatment cohorts included (1) vehicle (PBS) 2x/week; (2) cetuximab −20 mg/kg 2x/week; (3) bevacizumab −10 mg/kg 2x/week; or (4) the combination treatment both cetuximab (20 mg/kg) and bevacizumab (10 mg/kg) 2x/week.